Pharmacokinetic and pharmacodynamic properties of atenolol in acute myocardial infarction.
A commonly used combined intravenous (i.v.) and oral dose regimen of atenolol was evaluated in 21 patients with acute myocardial infarction (MI). Atenolol 5-10 mg was administered i.v. and was followed by 50 mg twice daily during the first 24 h. Starting on the second day, 100 mg was administered as a single dose. Dose adjustments were made as necessary. The i.v. dose resulted in a rapid plasma peak concentration, but absorption of the first oral dose appeared to be delayed. The half-life (t1/2) was significantly prolonged on day 2 as compared with day 6, but the tmax, Cmax, and area under the curve (AUC) were all comparable to what has been reported in patients without MI. The change in heart rate (HR) or blood pressure (BP) was not related to the initial plasma level of atenolol. The interindividual variation was large, but most patients obtained plasma levels of atenolol which in studies of other diseases have been shown to be effective.
Department of Medicine, Ostra Hospital, Gothenburg University, Sweden.
P
P
Held
C G
CG
Regårdh
K
K
Swedberg
D000328:Adult; D000368:Aged; D001262:Atenolol / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology
D001262:Atenolol